AbbVie
 
4Q Revenues: $6.8 billion (+6%)

4Q Earnings: $1.4 billion (-8%)

FY Revenues: $25.6 billion (+12%)

FY Earnings: $6.0 billion (+16%)

Comments: Humira sales were $16.1 billion for the year, up 15%. Imbruvica sales reached $1.8 billion for the year. Viekira sales were down 7% to $1.5 billion as a result of increased competition in the Hep C market. Lupron sales were pretty much flat at $821 million. Synagis sales were $730 million, down 2%. Synthroid sales were up 1% to $763 million. Creon sales were up 16% to $730 million. Kaletra sales were down 22% to $549 million.